Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: scomazzon e. Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5. Br J Haematol. 2019. PMID: 29974955 Free article. No abstract available.
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Martini V, Gattazzo C, Frezzato F, Trimarco V, Pizzi M, Chiodin G, Severin F, Scomazzon E, Guzzardo V, Saraggi D, Raggi F, Martinello L, Facco M, Visentin A, Piazza F, Brunati AM, Semenzato G, Trentin L. Martini V, et al. Among authors: scomazzon e. Br J Haematol. 2017 Jul;178(1):81-93. doi: 10.1111/bjh.14642. Epub 2017 Apr 17. Br J Haematol. 2017. PMID: 28419476 Free article.
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.
Visentin A, Imbergamo S, Frezzato F, Pizzi M, Bertorelle R, Scomazzon E, Berno T, Riva M, Piva E, Facco M, Piazza F, Semenzato G, Trentin L. Visentin A, et al. Among authors: scomazzon e. Oncotarget. 2017 Sep 28;8(66):110727-110731. doi: 10.18632/oncotarget.21304. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299182 Free PMC article.
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.
Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: scomazzon e. Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18. Br J Cancer. 2019. PMID: 31209327 Free PMC article.
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, Frezzato F, Trimarco V, Severin F, Raggi F, Scomazzon E, Pravato S, Piazza F, Semenzato G, Trentin L. Visentin A, et al. Among authors: scomazzon e. Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):678-685.e4. doi: 10.1016/j.clml.2019.03.002. Epub 2019 Mar 11. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31371221